Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 69.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,152 shares of the medical equipment provider's stock after selling 25,916 shares during the quarter. Wellington Management Group LLP's holdings in Zimmer Biomet were worth $1,178,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in ZBH. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $25,000. Menard Financial Group LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $30,000. Accredited Wealth Management LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $36,000. Kentucky Trust Co acquired a new stake in Zimmer Biomet during the fourth quarter worth about $39,000. Finally, OFI Invest Asset Management acquired a new stake in Zimmer Biomet during the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Trading Up 0.6%

Zimmer Biomet stock traded up $0.55 during trading on Friday, reaching $92.47. 1,003,196 shares of the company were exchanged, compared to its average volume of 1,801,629. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The company has a market capitalization of $18.30 billion, a P/E ratio of 20.78, a PEG ratio of 1.95 and a beta of 0.72. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock's 50 day simple moving average is $97.95 and its two-hundred day simple moving average is $104.14.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter last year, the business posted $1.94 earnings per share. The firm's revenue was up 1.1% compared to the same quarter last year. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Analyst Upgrades and Downgrades

Several analysts recently commented on ZBH shares. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research report on Monday, February 10th. Finally, Raymond James lowered their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $111.53.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.